Cell line · CVCL_1400
MDA-MB-175-VII
Cancer cell line, Homo sapiens. Invasive breast carcinoma of no special type. 43 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. MDA-MB-175-VII. Cell lines, record CVCL_1400. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_1400
On this page
Cell line
As Cellosaurus gives it.
- Name
- MDA-MB-175-VII
- Accession
- CVCL_1400
- RRID
- RRID:CVCL_1400
- Synonyms
- MDA MB 175 VII, MDA-MB-175VII, MDAMB175VII, MDA-MB-175, MDAMB175, MDA-175, MDA175, MD Anderson-Metastatic Breast-175-VII
- Species
- Homo sapiens (Human)
- Sex
- Female
- Age at sampling
- 56Y
- Category
- Cancer cell line
- Diseases
- Invasive breast carcinoma of no special type (NCIt C4194)
- Derived from
- Pleural effusion (metastatic)
- Entry created
- 2012-04-04
- Entry updated
- 2026-03-31
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers43
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| An Acrolein-Based Drug Delivery System Enables Tumor-Specific Sphingosine-1-Phosphate Targeting in Breast Cancer without Lymphocytopenia. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Siglec-7 and Siglec-9 expression in primary triple negative and oestrogen receptor positive breast cancer and in vitro signalling. | Clin Transl Immunology | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Placental co-transcriptional activator Vestigial-like 1 (VGLL1) drives tumorigenesis via increasing transcription of proliferation and invasion genes. | Front Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Avapritinib-based SAR studies unveil a binding pocket in KIT and PDGFRA. | Nat Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers. | Clin Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements. | Cancer Discov | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Effect of Wnt5a on drug resistance in estrogen receptor-positive breast cancer. | Breast Cancer | 2021 | Its Methods give the RRID and name the line | PubMed | |
| The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions. | Clin Cancer Res | 2021 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 43
See all 43 papersRelatives0
None in this release.
Cell banks4
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| ATCC | HTB-25 | ATCC | |
| AddexBio | C0006009/4885 | Cellosaurus | |
| CLS | 305825 | CLS | |
| NCBI_Iran | C432 | Cellosaurus |
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1400
GET https://conductscience.org/api/cell-lines/v1/CVCL_1400/papers?page=2